Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Feb 13, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to treat men with prostate cancer that has spread to certain nearby lymph nodes, specifically in cases where the cancer is still considered manageable. The study is called "Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response." It aims to see if a type of targeted radiation therapy called SBRT (Stereotactic Body Radiation Therapy) can help control the cancer and improve the length of time patients remain free from disease progression. Participants will receive radiation treatment focused on both the tumors and surrounding lymph nodes that might be at risk of developing cancer.

To be eligible for this trial, participants must have a confirmed diagnosis of prostate cancer and have specific types of lymph node involvement detected through imaging tests. They should also be in reasonably good health, meaning they can do everyday activities with some limitations. However, this trial is not open for enrollment yet, and it will not accept individuals who have had previous radiation therapy in the affected areas or other significant health issues that could complicate treatment. If eligible, participants can expect to undergo a series of focused radiation treatments under careful guidance to help manage their cancer effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically confirmed prostate adenocarcinoma.
• • 2. Oligorecurrent para-aortic +/- common iliac nodal disease planned for SBRT.
• • 3. ≤10 involved para-aortic (defined as between L1/L2 interface and L4/L5 interface) +/- common iliac LN on PSMA PET imaging.
• • 4. ECOG performance status 0-2.
• Exclusion Criteria:
• • 1. Prior radiotherapy to the nodal echelon (PA +/- common iliac).
• • 2. Active secondary malignancy, except for adequately treated non-melanoma skin cancer.
• • 3. Presence of significant comorbidities or medical conditions that may compromise the ability to undergo radiotherapy or participate in the study.
• • 4. Contraindication to radiation.